glp 1 in obesity Glucagon-like peptide the pathophysiology and pharmacotherapy of clinical Weighing the risk of GLP-1

State regulators are using consumer protection law, unfair trade practice statutes and public health authority to intervene in GLP-1 distribution channels that operate outside the bounds of federal drug law

If you'd rather watch and learn, here's our video that recaps the main content of this article

4 Future directions In this review, we have provided a comprehensive summary of the potential relationship between anti-inflammatory effects of GLP-1 and CAD

Treatment Decision-Making Treatment decision-making can be guided by the different mechanisms of action of AOMs to ascertain the suitability of the therapy for the individual patient

Safety profile comparison More effective does not always mean more side effects

As mentioned, albiglutide is no longer available, and thus, details on the HARMONY trial are not included in this clinical review